glp-1 alternative beverage aims to help consumers manage stress-related snacking The GLP-1 Agonists and Obesity:
Description
Chronic Disease Prevalence : Rising global rates of type 2 diabetes and obesity are expanding the patient pool for GLP1 therapies, increasing demand for both glycemic and weight management indications

Clinical Scoring Systems The U.S

HbA 1c , hemoglobin A 1c

February 2026

[DOI] [PubMed] [Google Scholar] [45].Consoli A, Formoso G

Methods In this open-label, single-center, casecontrol pilot study, patients with IIH (pwIIH) and a body mass index (BMI) of 30 kg/m 2 were offered to receive a GLP-1-RA (semaglutide, liraglutide) in addition to the usual care weight management (UCWM)
